Goldman Sachs analyst Richard Felton downgraded Fresenius Medical (FMS) to Neutral from Buy with a price target of EUR 40, down from EUR 55. The firm says the company has “several headwinds” in fiscal 2026. Goldman expects aother year of treatment volume growth below Fresenius Medical’s medium-term outlook. The company also faces a partial reversal of benefits accrued in 2025 from phosphate binders, potential headwinds from the expiry of Affordable Care Act subsidies, and incremental training costs, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Accelerates Second Tranche of €1 Billion Share Buyback
- Fresenius Medical to accelerate its share buyback program
- Fresenius Medical price target raised to $28 from $26 at Truist
- Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley
- Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds